Genomic and immunocyte characterisation of bloodstream infection caused by Klebsiella pneumoniae.


Journal

Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152

Informations de publication

Date de publication:
20 Jun 2024
Historique:
received: 04 04 2024
accepted: 18 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 20 6 2024
Statut: epublish

Résumé

The aim of this study was to evaluate the characteristics of immunocyte associated with bloodstream infection (BSI) caused by Klebsiella pneumoniae (Kpn). Patients with BSI-Kpn were included from 2015 to 2022 in our hospital. Immunocyte subpopulations of enrolled BSI-Kpn patients were tested on the same day of blood culture using multicolor flow cytometry analysis. Antibiotic susceptibility test was determined by agar dilution or broth dilution method. All included isolates were subjected to whole genome sequencing and comparative genomics analysis. Clinical and genetic data were integrated to investigate the risk factors associated with clinical outcome. There were 173 patients with non-duplicate BSI-Kpn, including 81 carbapenem-resistant Kpn (CRKP), 30 extended-spectrum β-lactamases producing Kpn (ESBL-Kpn), 62 none CRKP or ESBL-Kpn (S-Kpn). Among 68 ST11-CRKP isolates, ST11-O2v1:KL64 was the most common serotypes cluster (77.9%, 53/68), followed by ST11-OL101: KL47 (13.2%, 9/68). Compared with CSKP group, subpopulations of immunocyte in patients with CRKP were significantly lower (P < 0.01). In patients with ST11-O2v1:KL64 BSI-Kpn, the level of cytotoxic T lymphocytes (CD3 + CD8 +) is the highest, while the B lymphocytes (CD3-CD19 +) was the least. In addition, the level of immunocyte in patients with Kpn co-harbored clpV-ybtQ-qacE were lower than that in patients with Kpn harbored one of clpV, ybtQ or qacE and without these three genes. Furthermore, co-existence of clpV-ybtQ-qacE was independently associated with a higher risk for 30-day mortality. The results demonstrate that patients with BSI-CRKP, especially for ST11-O2v1:KL64, exhibit lower leukomonocyte counts. In addition, BSI-Kpn co-harbored clpV-ybtQ-qacE is correlated to higher 30-day mortality.

Identifiants

pubmed: 38902832
doi: 10.1186/s12941-024-00721-3
pii: 10.1186/s12941-024-00721-3
doi:

Substances chimiques

beta-Lactamases EC 3.5.2.6
Anti-Bacterial Agents 0
Carbapenems 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56

Subventions

Organisme : Zhejiang Provincial Natural Science Foundation of China
ID : LTGY24H190002

Informations de copyright

© 2024. The Author(s).

Références

Chen Y, Ji J, Ying C, Liu Z, Yang Q, Kong H, Xiao Y, Blood Bacterial Resistant Investigation Collaborative System (BRICS) Study Group. Blood bacterial resistant investigation collaborative system (BRICS) report: a national surveillance in China from 2014 to 2019. Antimicrob Resist Infect Control. 2022;11(1):17. https://doi.org/10.1186/s13756-022-01055-5 .
doi: 10.1186/s13756-022-01055-5 pubmed: 35074014 pmcid: 8785473
Kern WV, Rieg S. Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect. 2020;26(2):151–7. https://doi.org/10.1016/j.cmi.2019.10.031 .
doi: 10.1016/j.cmi.2019.10.031 pubmed: 31712069
Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2017;38(11):1319–28. https://doi.org/10.1017/ice.2017.197 .
doi: 10.1017/ice.2017.197 pubmed: 28950924
Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022;60(3): 106633. https://doi.org/10.1016/j.ijantimicag.2022.106633 .
doi: 10.1016/j.ijantimicag.2022.106633 pubmed: 35787918
Yu W, Shen P, Chen Y, Zhou K, Chi X, Xiao Y. Epidemiology and genomic characteristics of bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae with decreased susceptibility to aztreonam/avibactam in China. Front Cell Infect Microbiol. 2022;12: 926209. https://doi.org/10.3389/fcimb.2022.926209 .
doi: 10.3389/fcimb.2022.926209 pubmed: 35811669 pmcid: 9257070
Bengoechea JA, Sa PJ. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43(2):123–44. https://doi.org/10.1093/femsre/fuy043 .
doi: 10.1093/femsre/fuy043 pubmed: 30452654
Wong Fok Lung T, Charytonowicz D, Beaumont KG, Shah SS, Sridhar SH, Gorrie CL, Mu A, Hofstaedter CE, Varisco D, McConville TH, Drikic M, Fowler B, Urso A, Shi W, Fucich D, Annavajhala MK, Khan IN, Oussenko I, Francoeur N, Smith ML, Stockwell BR, Lewis IA, Hachani A, Upadhyay Baskota S, Uhlemann AC, Ahn D, Ernst RK, Howden BP, Sebra R, Prince A. Klebsiella pneumoniae induces host metabolic stress that promotes tolerance to pulmonary infection. Cell Metab. 2022;34(5):761-774.e9. https://doi.org/10.1016/j.cmet.2022.03.009 .
doi: 10.1016/j.cmet.2022.03.009 pubmed: 35413274 pmcid: 9081115
Ahn D, Bhushan G, McConville TH, Annavajhala MK, Soni RK, Wong Fok Lung T, Hofstaedter CE, Shah SS, Chong AM, Castano VG, Ernst RK, Uhlemann AC, Prince A. An acquired acyltransferase promotes Klebsiella pneumoniae ST258 respiratory infection. Cell Rep. 2021;35(9):109196. https://doi.org/10.1016/j.celrep.2021.109196 .
doi: 10.1016/j.celrep.2021.109196 pubmed: 34077733 pmcid: 8283688
Feriotti C, Sá-Pessoa J, Calderón-González R, Gu L, Morris B, Sugisawa R, Insua JL, Carty M, Dumigan A, Ingram RJ, Kissenpfening A, Bowie AG, Bengoechea JA. Klebsiella pneumoniae hijacks the Toll-IL-1R protein SARM1 in a type I IFN-dependent manner to antagonize host immunity. Cell Rep. 2022;40(6): 111167. https://doi.org/10.1016/j.celrep.2022.111167 .
doi: 10.1016/j.celrep.2022.111167 pubmed: 35947948 pmcid: 9638020
Dolgachev VA, Yu B, Sun L, Shanley TP, Raghavendran K, Hemmila MR. Interleukin 10 overexpression alters survival in the setting of gram-negative pneumonia following lung contusion. Shock. 2014;41(4):301–10. https://doi.org/10.1097/SHK.0000000000000123 .
doi: 10.1097/SHK.0000000000000123 pubmed: 24430542 pmcid: 4019007
Chen Y, Ying S, Jiang L, Dong S, Dai J, Jin X, Yu W, Qiu Y. A Novel nomogram for predicting risk factors and outcomes in bloodstream infections caused by Klebsiella pneumoniae. Infect Drug Resist. 2022;15:1317–28. https://doi.org/10.2147/IDR.S349236 .
doi: 10.2147/IDR.S349236 pubmed: 35378894 pmcid: 8976504
Pan H, Lou Y, Zeng L, Wang L, Zhang J, Yu W, Qiu Y. Infections caused by carbapenemase-producing Klebsiella pneumoniae: microbiological characteristics and risk factors. Microb Drug Resist. 2019;25(2):287–96. https://doi.org/10.1089/mdr.2018.0339 .
doi: 10.1089/mdr.2018.0339 pubmed: 30810470 pmcid: 6441289
Guo W, Lian X, Li H, Jiang L, Chen Y, Shen P, Yu W. Characteristics of immunocytes and cytokines in patients with bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae in China. Infect Drug Resist. 2024;17:719–25. https://doi.org/10.2147/IDR.S431207 .
doi: 10.2147/IDR.S431207 pubmed: 38410794 pmcid: 10896100
Chen C, Chen H, Zhang Y, Thomas HR, Frank MH, He Y, Xia R. TBtools: an integrative toolkit developed for interactive analyses of big biological data. Mol Plant. 2020;13(8):1194–202. https://doi.org/10.1016/j.molp.2020.06.009 .
doi: 10.1016/j.molp.2020.06.009 pubmed: 32585190
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 32th informational supplement 2022. 2022. http://www.clsi.org/ .
Yu W, Luo Q, Shen P, Chen Y, Xu H, Xiao Y, Qiu Y. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae. Int J Antimicrob Agents. 2021;58(6): 106458. https://doi.org/10.1016/j.ijantimicag.2021.106458 .
doi: 10.1016/j.ijantimicag.2021.106458 pubmed: 34706255
Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes De Novo assembler. Curr Protoc Bioinformatics. 2020;70(1): e102. https://doi.org/10.1002/cpbi.102 .
doi: 10.1002/cpbi.102 pubmed: 32559359
Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–9. https://doi.org/10.1093/bioinformatics/btu153 .
doi: 10.1093/bioinformatics/btu153 pubmed: 24642063
Gardner SN, Slezak T, Hall BG. kSNP3.0: SNP detection and phylogenetic analysis of genomes without genome alignment or reference genome. Bioinformatics. 2015;31(17):2877–8. https://doi.org/10.1093/bioinformatics/btv271 .
doi: 10.1093/bioinformatics/btv271 pubmed: 25913206
Wyres KL, Wick RR, Gorrie C, Jenney A, Follador R, Thomson NR, Holt KE. Identification of Klebsiella capsule synthesis loci from whole genome data. Microb Genom. 2016;2(12): e000102. https://doi.org/10.1099/mgen.0.000102 .
doi: 10.1099/mgen.0.000102 pubmed: 28348840 pmcid: 5359410
Gonzalez-Ferrer S, Peñaloza HF, Budnick JA, Bain WG, Nordstrom HR, Lee JS, Van Tyne D. Finding order in the chaos: outstanding questions in Klebsiella pneumoniae pathogenesis. Infect Immun. 2021;89(4):e00693-e720. https://doi.org/10.1128/IAI.00693-20 .
doi: 10.1128/IAI.00693-20 pubmed: 33558323 pmcid: 8090965
Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–59. https://doi.org/10.1038/s41579-019-0315-1 .
doi: 10.1038/s41579-019-0315-1 pubmed: 32055025
Zhou K, Xue CX, Xu T, Shen P, Wei S, Wyres KL, Lam MMC, Liu J, Lin H, Chen Y, Holt KE, Xiao Y, BRICS Working Group. A point mutation in recC associated with subclonal replacement of carbapenem-resistant Klebsiella pneumoniae ST11 in China. Nat Commun. 2023;14(1):2464. https://doi.org/10.1038/s41467-023-38061-z .
doi: 10.1038/s41467-023-38061-z pubmed: 37117217 pmcid: 10147710
Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis. 2017;215(suppl_1):S18–27. https://doi.org/10.1093/infdis/jiw378 .
doi: 10.1093/infdis/jiw378 pubmed: 28375514 pmcid: 5853309
Ernst CM, Braxton JR, Rodriguez-Osorio CA, Zagieboylo AP, Li L, Pironti A, Manson AL, Nair AV, Benson M, Cummins K, Clatworthy AE, Earl AM, Cosimi LA, Hung DT. Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae. Nat Med. 2020;26(5):705–11. https://doi.org/10.1038/s41591-020-0825-4 .
doi: 10.1038/s41591-020-0825-4 pubmed: 32284589 pmcid: 9194776
Gross WL, Rucks A. Klebsiella pneumoniae stimulate highly purified human blood B cells to mature into plaque forming cells without prior proliferation. Clin Exp Immunol. 1983;52(2):372–80.
pubmed: 6190601 pmcid: 1535840
Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26(2):185–230. https://doi.org/10.1128/CMR.00059-12 .
doi: 10.1128/CMR.00059-12 pubmed: 23554414 pmcid: 3623377
Li Y, Shen H, Zhu C, Yu Y. Carbapenem-resistant Klebsiella pneumoniae infections among ICU admission patients in central China: prevalence and prediction model. Biomed Res Int. 2019;2019:9767313. https://doi.org/10.1155/2019/9767313 . (eCollection 2019).
doi: 10.1155/2019/9767313 pubmed: 31032370 pmcid: 6457282
Blondel CJ, Jiménez JC, Leiva LE, Alvarez SA, Pinto BI, Contreras F, Pezoa D, Santiviago CA, Contreras I. The type VI secretion system encoded in Salmonella pathogenicity island 19 is required for Salmonella enterica serotype Gallinarum survival within infected macrophages. Infect Immun. 2013;81(4):1207–20. https://doi.org/10.1128/IAI.01165-12 .
doi: 10.1128/IAI.01165-12 pubmed: 23357385 pmcid: 3639620
Lawlor MS, O’connor C, Miller VL. Yersiniabactin is a virulence factor for Klebsiella pneumoniae during pulmonary infection. Infect Immun. 2007;75(3):1463–72. https://doi.org/10.1128/IAI.00372-06 .
doi: 10.1128/IAI.00372-06 pubmed: 17220312 pmcid: 1828572
Paulsen IT, Littlejohn TG, Rådström P, Sundström L, Sköld O, Swedberg G, Skurray RA. The 3′ conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and disinfectants. Antimicrob Agents Chemother. 1993;37(4):761–8. https://doi.org/10.1128/AAC.37.4.761 .
doi: 10.1128/AAC.37.4.761 pubmed: 8494372 pmcid: 187754

Auteurs

Wei Yu (W)

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Chen Huang (C)

Department of Respiratory Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, China.

Xiang Lian (X)

Department of Infectious Diseases, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Xiangshan First People's Hospital Medical and Health Group, Ningbo Fourth Hospital, Ningbo, China.

Lushun Jinag (L)

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Hong Li (H)

Department of Infectious Diseases, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Xiangshan First People's Hospital Medical and Health Group, Ningbo Fourth Hospital, Ningbo, China.

Ping Shen (P)

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. shenping123451@126.com.

Yonghong Xiao (Y)

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. xiaoyonghong@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH